Anabwani 1999.

Methods	Randomized controlled trial Length of follow up: 28 d Generation of allocation sequence: random assignment of study number Allocation concealment: unclear Blinding: none Inclusion of all randomized participants in the analysis: 164 analysed/168 randomized (97.6%)
Participants	Number: 168 enrolled; 164 analysed; 4 discontinued intervention and were excluded Age range: 3 to 12 years Gender: male and female Inclusion criteria: age 3 to 12 years; uncomplicated malaria; fever; parasitaemia between 1000 to 200,000 parasites/µL; ability to tolerate oral therapy; weight > 10 kg; written informed consent given by parent or guardian Exclusion criteria: severe or cerebral malaria; prolonged QTc interval (above 0.44 s); mixed infections with other Plasmodium species; concomitant disease
Interventions	1. Atovaquone‐proguanil (60 mg/kg atovaquone and 24 mg/kg proguanil over 3 d) 2. Halofantrine (24 mg/kg over 12 h)
Outcomes	1. 28‐d cure rate 2. Parasite clearance time 3. Fever clearance time 4. Adverse events
Notes	Location: Kenya Drug resistance: not stated